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The aim of this paper is to provide guidelines for performing 
Mendelian randomization investigations. It is written both for 
practitioners seeking to undertake analyses and write up their 
findings, and for journal editors and reviewers seeking to 
assess Mendelian randomization manuscripts. These guidelines 
are deliberately written as suggestions and recommendations 
rather than as prescriptive rules, as we believe that there is no 
recipe or single “right way” to perform a Mendelian randomiza-
tion investigation. Best practice will depend on the aim of the 
investigation and the specific exposure and outcome variables. 
However, we believe these guidelines will help investigators to 
consider the key issues in designing, undertaking and present-
ing Mendelian randomization analyses. These guidelines will be 
updated based on feedback from the community and advances 
in the field. Updates will be made periodically as needed, and at 
least every 18 months.
These guidelines are complementary to the STROBE-MR 
recommendations on reporting Mendelian randomization 
investigations1. Here, we provide advice on which analyses to 
perform in a Mendelian randomization investigation, whereas 
the STROBE-MR guidelines focus on reporting the analyses 
chosen by the investigators. We assume a familiarity with 
the basic concepts of Mendelian randomization and genetic 
epidemiology, such as pleiotropy and linkage disequilibrium2–4. 
We use the term “exposure” to refer to the proposed causal 
factor, and “outcome” to refer to the factor or condition that the 
exposure is hypothesized to influence.
Flowcharts highlighting some of the key analytic steps and 
choices for investigators are provided as Figure 1 and 
Figure 2, and a one-page checklist summarizing these guide-
lines written for reviewers of Mendelian randomization 
analyses is provided as Figure 3. The guidelines are divided 
into nine sections: motivation and scope, data sources, choice of 
genetic variants, variant harmonization, primary analysis, 
supplementary and sensitivity analyses (one section on robust 
statistical methods and one on other approaches), data presen-
tation, and interpretation. Software to implement the statistical 
methods is referenced in Table 1.
1. Motivation and scope
Mendelian randomization uses genetic variants to assess causal 
relationships in observational data. A genetic variant can be 
considered as an instrumental variable for a given exposure if it 
satisfies the instrumental variable assumptions: it is associated 
with the exposure in a specific way, meaning that it does not 
affect the outcome except via the exposure, and it is not associated 
with the outcome due to confounding5,6. Before embarking 
on a Mendelian randomization analysis, investigators should 
consider the aims of their investigation and the primary hypoth-
esis of interest. There are many potential motivations for using 
Mendelian randomization, and the motivation should influ-
ence decisions on how to perform the analysis, and how to 
arrange and present its results. The objective of a Mendelian 
randomization analysis is a test of a causal hypothesis, and often 
additionally an estimate of a causal effect7. The straightforward 
statement of the causal hypothesis is that interventions in the 
exposure variable will affect the outcome. If the genetic asso-
ciations with the exposure vary with time, then there are some 
nuances in terms of what causal hypotheses can be tested8; we 
discuss the impact of time-varying relationships between 
variables in Section 9.
If a Mendelian randomization investigation is performed 
primarily to assess whether an exposure has a causal effect on 
an outcome, then estimating the size of the causal effect of 
the exposure on the outcome is less important and may even be 
unnecessary7,9. For example, Mendelian randomization has 
demonstrated a causal effect of time spent in formative education 
on Alzheimer’s disease10. However, those at risk of Alzheimer’s 
disease are unable to extend their time in formative education. 
The analysis tests a meaningful causal hypothesis, but the size 
of the causal estimate has limited utility. Priorities in such 
an analysis are to find genetic variants that satisfy the instrumen-
tal variable assumptions and to test their associations with the 
outcome in the largest available dataset that is relevant to the 
causal question of interest.
In contrast, if investigators seek to estimate the quantitative 
impact on the outcome of a proposed intervention in the 
exposure11, then further questions become more important, such 
as how well the genetic variant proxies the specific intervention, 
whether genetic associations with the exposure are estimated 
in a relevant population, and whether the relationships between 
variables are linear and homogeneous in the population12. 
However, as we discuss in Section 9, causal estimates from Men-
delian randomization should always be interpreted with cau-
tion. Alternatively, if investigators simply want to assess whether 
traits share common genetic predictors (potentially implying 
shared aetiological mechanisms), then an analytic approach 
that assesses shared heritability (such as LD-score regression13 
or the latent causal variable method14) may be preferable 
to conducting a Mendelian randomization investigation.
Investigators should also give thought to the scope of their 
analysis. If the aim of the investigation is to understand dis-
ease aetiology, then consideration of a limited set of exposures/ 
outcomes as main analyses may be justified, whereas if the 
question relates to public health, then consideration of a broad 
range of outcomes influenced by an exposure may be worth-
while. At the extreme end of the spectrum is a phenome-wide 
Mendelian randomization investigation, in which very large 
numbers of exposure/outcome pairs are considered15–17. 
      Amendments from Version 1
We have updated the manuscript to address the reviewers’ 
concerns. Updates include relating to reverse causation, 
pleiotropy and instrument invalidity, time, and the interpretation of 
estimates.
Any further responses from the reviewers can be found at the 
end of the article
REVISED
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Figure 1. Flowchart highlighting some of the key analytic choices in performing a Mendelian randomization (MR) analysis.
Figure 2. Generic analytic pipeline for Mendelian randomization (MR).
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Figure 3. Checklist of questions to consider when reviewing a Mendelian randomization investigation.
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Such analyses are generally regarded as exploratory or 
“hypothesis-generating”, and results are typically treated as 
provisional until replicated in an independent dataset.
Specifying the primary analyses in a Mendelian randomization 
investigation is important to address problems of multiple 
testing, particularly given the large number of analyses that 
could be performed using available genetic data28. Additional 
analyses, including subgroup analyses and analyses on related 
outcomes may be presented as supplementary, exploratory, or 
sensitivity analyses. An overly conservative approach to multiple 
testing is often excessive, given the typically low power of 
Mendelian randomization studies and the fact that Mendelian 
randomization typically investigates exposure/outcome rela-
tionships with prior epidemiological or biological support. 
As with all epidemiological analyses, it is good practice 
to avoid selective reporting of “significant” results (leading 
to reporting bias) and to describe transparently all analyses 
performed.
2. Data sources
The next fundamental question is which data sources will be 
used: how many datasets are included in the analysis and 
whether the analysis is performed using individual-level data or 
summarized data.
Mendelian randomization investigations can be performed using 
data from a single sample (known as one-sample Mendelian ran-
domization), in which genetic variants, exposure, and outcome 
are measured in the same individuals, or from two samples 
(known as two-sample Mendelian randomization), in which 
variant—exposure associations are estimated in one dataset, 
and variant—outcome associations are estimated in a second 
dataset29. Two-sample investigations often occur when genetic 
associations with the exposure are estimated in a cross-sectional 
sample of healthy individuals, to reflect genetic associations 
with usual levels of the exposure in the population, and genetic 
associations with a binary disease outcome are estimated in 
a case-control study.
There are benefits and limitations of both one- and two-sample 
settings. A one-sample setting allows the investigation to be 
conducted in a single population sample, meaning that 
Mendelian randomization and conventional epidemiological find-
ings (for example from multivariable-adjusted regression) can 
be compared in the same individuals. In a two-sample setting, 




Strengths and weaknesses Reference Software
Inverse-variance 
weighted
All variants valid or 
balanced pleiotropy
Most efficient (greatest statistical power), biased if average 
pleiotropic effect differs from zero
18 *†
MR-Egger InSIDE Sensitive to outliers, sensitive to violations of InSIDE assumption, 
InSIDE assumption often not plausible, often less efficient
19 *†
Weighted median Majority valid Robust to outliers, sensitive to addition/removal of genetic variants 20 *†
Mode-based 
estimation
Plurality valid Robust to outliers, sensitive to bandwidth parameter and addition/
removal of genetic variants, generally conservative
21 *†
MR-PRESSO Outlier-robust Removes outliers, efficient with valid IVs, very high false positive 
rate with several invalid IVs
22 ‡
MR-Robust Outlier-robust Downweights outliers, efficient with valid IVs, high false positive 
rate with several invalid IVs
23 *
MR-Lasso Outlier-robust Removes outliers, efficient with valid IVs, high false positive rate 
with several invalid IVs
23
MR-RAPS Balanced pleiotropy 
(except outliers)





Plurality valid Robust to outliers, sensitive to variance parameter and addition/
removal of genetic variants
25 *
MR-Mix Plurality valid Robust to outliers, requires large numbers of genetic variants, 
very high false positive rate in several scenarios
26 ‡
Each of the methods in the table can be implemented using summarized data. False positive rates refer to the simulation study by Slob and Burgess27. InSIDE 
is the Instrument Strength Independent of Direct Effect assumption.
* Implemented in MendelianRandomization package for R (https://cran.r-project.org/web/packages/MendelianRandomization/index.html)
† Implemented in mrrobust package for Stata (https://github.com/remlapmot/mrrobust)
‡ Implemented for R in its own software package:
- MR-PRESSO in mrpresso package (https://github.com/rondolab/MR-PRESSO),
- MR-RAPS in mr.raps package (https://github.com/qingyuanzhao/mr.raps),
- MR-Mix in MRMix package (https://github.com/gqi/MRMix).
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the populations from which the two samples were extracted may 
differ. This is problematic if associations of the genetic vari-
ant with the exposure or with variables on pleiotropic pathways 
differ between the two samples, as this could affect the validity of 
the instrumental variable assumptions. A particular concern arises 
if the two samples represent different ethnic groups, as patterns 
of linkage disequilibrium can differ between populations, mean-
ing that a genetic variant may not be as strongly (or even not at 
all) associated with the exposure in the outcome dataset. Alter-
natively, the two samples could differ substantially according to 
population characteristics such as age, sex, socio-economic 
background, and so on8,30. Such differences can affect not 
only the interpretation of causal estimates, but also the valid-
ity of causal inferences31. For example, genetic variants 
associated with smoking intensity may be strongly associ-
ated with disease outcomes in populations where smoking is 
common, but not in populations where smoking is rare. 
One-sample analyses do not suffer from these concerns, nor 
do they require harmonization of the genetic variants across the 
datasets (see Section 4).
Another related issue is whether the analysis is performed using 
individual-level data or summarized data. Summarized data 
are genetic association estimates from regression of the expo-
sure or outcome on a genetic variant18,32. Several large consor-
tia have made such estimates publicly available for hundreds of 
thousands of variants28,33. Although the use of summarized data 
is often synonymous with the two-sample setting, the benefits 
and limitations for the analysis of the two choices (i.e. one- vs 
two-sample and individual-level vs summarized data) are distinct. 
Summarized data are often available for larger sample sizes, 
meaning that power to detect a causal effect is increased. However, 
access to only summarized data limits the range of analyses that 
can be performed. Individual-level data are required to conduct 
analyses in specific subgroups or strata of the population, or to 
choose which variables to adjust for when generating the sum-
marized data. If published summarized association estimates 
have already been adjusted for a variable causally downstream 
of the exposure or outcome, collider bias (see Section 7) may be 
unavoidable. Individual data in a one-sample setting are required 
to investigate non-linear effects34,35. An advantage of publicly 
available summarized data is transparency, as the analysis can 
be reproduced by a third party with access to the same data.
One- and two-sample investigations also differ in terms of bias 
with weak instruments36. In a one-sample setting, if the genetic 
variant–exposure associations are weak, then chance variation 
means that genetic associations with the exposure and outcome 
are correlated in the direction of the confounded association 
between the two. This results in instrumental variable estimates 
that are biased in the direction of the confounded association, 
and inflated false positive (type 1 error) rates, particularly when 
more than one variant is included in the analysis37. In a two-sample 
setting without sample overlap, bias due to weak instruments 
is in the direction of the null, and does not lead to false positive 
findings. However, as several large consortia have overlapping 
studies, participants may overlap between the datasets used to esti-
mate the genetic associations with the exposure and outcome38. 
In this case, the direction and size of the bias varies linearly 
depending on the degree of overlap (formally, depending on the 
degree of correlation between the genetic association estimates). 
For the special case of a one-sample analysis with a binary 
disease outcome, if the genetic associations with the exposure are 
estimated in the controls only, then genetic associations with the 
exposure and outcome will not be correlated, and bias will follow 
the pattern of the two-sample setting38.
3. Selection of genetic variants
The most important decision to be made in designing a Mendelian 
randomization investigation is which genetic variants to include 
in the analysis39. First, it is necessary to decide whether the 
analysis is performed using variants from a single gene region, 
or using variants from multiple regions of the genome (a 
polygenic analysis). For example, a Mendelian randomization 
analysis for C-reactive protein may be conducted using variants 
in the neighbourhood of the CRP gene region (which encodes 
C-reactive protein), or it may be conducted using all independ-
ent genome-wide significant predictors of C-reactive protein40. 
The former has advantages of specificity – if a gene region has 
a specific biological link with the exposure, then the Mendelian 
randomization investigation is more plausible as an assess-
ment of the causal role of that particular exposure. However, if 
only one gene region is included in the analysis, then several 
robust statistical analysis methods (see Section 6) are not 
possible, as they assume independence in whether variants violate 
the instrumental variable assumptions. Variants in the same gene 
region are likely to either all be valid instruments or all invalid. 
Additionally, when genetic variants are all valid instruments, 
power is maximized when genetic variants explain the greatest pro-
portion of variance in the exposure41 – hence a polygenic Mendelian 
randomization investigation will typically have greater power than 
one including variants only from a single gene region.
When the analysis is based on a single gene region, it may be 
that a single variant is included in the analysis. However, if 
there are multiple variants that explain independent variance in 
the exposure, then their inclusion will increase power to detect 
a causal effect, even if the variants are partially correlated. With 
summarized data, appropriate methods should be used to account 
for correlated variants30. If variants in a gene region can be 
thought of as proxies for an intervention that targets the exposure 
(such as variants in the HMGCR gene region for statin drugs), 
then the analysis has particular relevance for predicting the 
effect of that intervention.
For a polygenic analysis, there are two main strategies for 
selecting variants: either a biologically driven approach or a 
statistically driven approach. The two approaches are not mutu-
ally exclusive, and the overall decision of which variants to 
include may comprise elements from both approaches.
A biological approach to the selection of genetic variants would 
be to include variants from regions that have a biological link to 
the exposure of interest. For example, several Mendelian rand-
omization investigations for vitamin D have used variants from 
four gene regions that are biologically implicated in the synthesis 
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or metabolism of vitamin D42. However, caution is required as 
biological understanding is rarely infallible. As an exam-
ple, although genetic variants in the IL6R gene region are 
associated with increased circulating levels of interleukin-
6, they in fact decrease interleukin-6 signalling, leading to 
opposite directions of association with disease outcomes to 
those expected based on serum interleukin-6 measurements43.
A common statistical approach when selecting genetic variants 
is to include all variants that are associated with the exposure 
of interest at a given level of statistical significance (typically, 
a genome-wide significance threshold, such as p < 5×10-8). 
Often, selection is based on the dataset in which genetic asso-
ciations with the exposure are estimated. However, this 
leads to “winner’s curse” –genetic associations tend to be 
overestimated in the dataset in which they were first discov-
ered. If genetic variants are selected based on their associations 
with the exposure in the dataset under analysis, weak instrument 
bias is exacerbated (in the direction of the observational asso-
ciation in a one-sample setting, and in the direction of the null 
in a two-sample setting)37. Bias can be avoided by selecting 
genetic variants based on a different dataset entirely. This can 
lead to a “three-sample” analysis, in which variants are identified 
in one dataset, and the genetic associations with the exposure 
and outcome are estimated in separate datasets44. If genetic 
variants are chosen solely based on their association with the 
exposure without reference to the function of the variants, then 
researchers should be especially careful about the possibility of 
variants being pleiotropic.
A more nuanced approach to variant selection would be to start 
off with a statistical rationale for choosing genetic variants, but 
then to exclude variants that are known to be pleiotropic or that 
are associated with variables that represent pleiotropic path-
ways to the outcome. However, a genetic association with a 
variable does not necessarily reflect that the instrumental variable 
assumptions are violated.
We use the term “horizontal pleiotropy” (sometimes referred to 
as simply “pleiotropy”) to refer to the scenario where a genetic 
variant is associated with variables on different causal pathways 
to the outcome, and “vertical pleiotropy” (sometimes referred to 
as “indirect pleiotropy” or “mediated pleiotropy”) to refer to the 
scenario where a genetic variant is associated with variables that 
are on the same causal pathway to the outcome45. Provided that 
the causal pathway from the genetic variant to the outcome is 
mediated entirely via the exposure (see Figure 4), a genetic 
variant is a valid instrument for assessing the causal role of the 
Figure 4. Directed acyclic graphs illustrating validity and invalidity of instrumental variable assumptions in different scenarios. 
a) Mediator is on causal pathway from exposure to outcome. b) Mediator is on causal pathway from genetic variants to exposure. c) Genetic 
variants influence the exposure, which has downstream effect on a related variable which does not affect the outcome. d) Genetic variants 
influence a related variable, and the related variable affects the outcome and exposure of interest. e) Genetic variants influence the outcome 
primarily, and only influence the exposure via the outcome. We note that the related variable may be known or unknown. 
In scenarios a, b, and c, as there is no alternative pathway from the genetic variants to the outcome, the instrumental variable assumptions are 
satisfied. In scenario d, the pathway from the genetic variants to the outcome does not pass via the exposure, and so the instrumental variable 
assumptions are not satisfied for the exposure (although they are satisfied for the related variable). Scenarios a, b, and c are examples of 
“vertical pleiotropy” that do not invalidate the instrumental variable assumptions. Scenario d reflects a situation where the causal risk factor 
has been incorrectly identified – it is not the exposure, but the related variable. Scenario e reflects a reverse causation situation where the 
genetic variant has been incorrectly identified as primarily affecting the exposure.
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exposure (assuming the other instrumental variable assump-
tions are satisfied), even if it is associated with another variable29. 
In practice, distinguishing between horizontal pleiotropy and 
vertical pleiotropy requires knowledge of the relationships between 
the variables in the analysis. When there are multiple genetic vari-
ants, horizontal pleiotropy is more likely if a genetic association 
with a specific variable is only observed for a small number of 
variants. In contrast, vertical pleiotropy (in particular correspond-
ing to the scenarios in Figure 4a–c) is likely to lead to genetic 
associations with that variable for all variants that associate with 
the exposure. While removing horizontally pleiotropic variants 
from a Mendelian randomization analysis should lead to more 
reliable results, care must be exercised, as removing vertically 
pleiotropic variants could lead to distorted causal estimates. 
Another possible scenario that would lead to instrument invalid-
ity is if genetic variants influence the outcome primarily rather 
than the exposure (Figure 4e, see also discussion on reverse 
causation in Section 7). If there is a reverse causal effect of the 
outcome on the exposure, then genetic predictors of the 
outcome would be identified as hits in a genome-wide association 
study for the exposure. However, such variants would not be 
valid instrumental variables.
In conclusion, there is no one correct way to choose which 
genetic variants to include in an analysis. Causal conclusions 
will be more reliable when the instrumental variable assumptions 
are more plausible. Generally speaking, this means that analy-
ses of exposures such as proteins conducted using variants in a 
coding gene region for the protein (referred to as “cis-variants”), 
or otherwise where variants having biological relevance to the 
exposure can be found, are likely to be more credible. Analy-
ses based on cis-variants only are also likely to be more reliable 
for assessing the causal role of molecular phenotypes such as 
gene expression and DNA methylation. However, in many cases 
(and particularly for multifactorial exposures such as body mass 
index or blood pressure), it is not possible to find a cis-variant, 
and so a more agnostic polygenic analysis may be necessary. 
This allows investigators to test for consistency of the causal 
finding across multiple variants that influence the exposure via 
different biological pathways. A balance needs to be struck 
between including fewer variants (and potentially having 
insufficient power) and including more variants (and potentially 
including pleiotropic variants).
A practical suggestion for performing a polygenic analysis is 
to consider both a liberal analysis, including more genetic vari-
ants, and a conservative analysis, including fewer variants29. 
While it is theoretically possible for pleiotropy to lead to a false 
negative finding, it is generally more likely that pleiotropy will 
bias estimates away from the null. Hence a null finding in a 
liberal analysis is more convincing evidence of a true null 
relationship – there is little evidence for a causal relationship 
even when potentially pleiotropic genetic variants are included in 
the analysis. Section 6 describes sensitivity analyses for assessing 
the instrumental variable assumptions and the robustness 
of non-null findings.
4. Variant harmonization
Genetic associations with exposures and outcomes are typi-
cally reported per additional copy of a particular allele. Hence, 
when combining summarized data on genetic associations, it is 
important to ensure that genetic associations are expressed per 
additional copy of the same allele46. This is particularly important 
as not all publicly-available data resources are consistent about 
reporting strand information correctly. For example, if a genetic 
variant is a biallelic single nucleotide polymorphism (SNP) 
with alleles A and G on the positive strand, then the correspond-
ing base pairs on the negative strand will be T and C. In this 
case, one dataset may report the association per additional copy 
of the A allele, and another per additional copy of the T allele – 
but the same comparison is being made. Allele and strand infor-
mation can be double-checked by comparing allele frequency 
information – if the allele frequencies are similar for the A and T 
alleles, then the researcher can be more confident that this is a 
strand mismatch. Additional care should be taken for palindromic 
variants – if the alleles were A and T (or C and G), then the same 
alleles would appear on both the positive and negative strands. 
In such a case, if the allele frequency is close to 50%, it may be 
necessary to drop the variant from the analysis if it is not possi-
ble to verify that the alleles have been correctly orientated. While 
this is a conservative recommendation, allele alignment prob-
lems have led to incorrect results in Mendelian randomization 
analyses, and retractions and corrections of manuscripts47.
5. Primary analysis
Different statistical methods have been proposed for Mendelian 
randomization with individual-level data and with summarized 
data. In a one-sample setting with individual-level data, a causal 
effect estimate can be obtained using the two-stage least-squares 
(2SLS) method. In the first stage, the exposure is regressed 
on the genetic variants and any relevant covariates. In the 
second stage the outcome is then regressed on the predicted 
values of the exposure from the first regression and the same 
covariates48. In general, we recommend only including as cov-
ariates age, sex, genomic principal components of ancestry, and 
technical covariates (such as recruitment centre), as further adjust-
ment may bias estimates either if adjustment is for a variable 
on the causal pathway from the genetic variants to the outcome 
(a mediator), or if adjustment induces collider bias49. Strictly 
speaking, the 2SLS method refers to a two-stage analysis using 
linear regression for continuous outcomes and exposures. Simi-
lar two-stage analyses can be performed with binary variables 
using logistic regression50, although in this case estimates are 
sensitive to correct specification of the first-stage regression 
model51 and other approaches that make weaker distributional 
assumptions, such as structural mean models, may be preferred52.
The 2SLS method can be applied to the two-sample setting if 
individual-level data are available for both samples53. However, 
it is typical for two-sample investigations to use summarized 
data. With summarized data, if only one genetic variant is used 
as an instrument, the causal effect estimate is simply the ratio 
of the variant—outcome association to the variant—exposure 
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association. With multiple variants as instruments, the most com-
monly used method is the inverse-variance weighted (IVW) 
method18. With uncorrelated variants, the IVW estimate can be 
obtained from an IVW meta-analysis of the ratio estimates for 
the individual variants54. The same estimate can equivalently 
be calculated as the ratio estimate using a weighted genetic 
risk score as a single instrument, with the weights equal to the 
associations of each variant with the exposure estimated in the 
first sample30. A modification of this method has been proposed to 
allow for correlation (linkage disequilibrium) between variants30. 
For continuous outcomes, the IVW estimate is asymptotically 
equivalent to the 2SLS estimate obtained from individual level 
data18. The 2SLS method (and thus also the IVW method) is the 
most efficient estimate of the causal effect when all genetic 
variants are valid instruments30.
If all genetic variants are valid instruments and the relationships 
between all variables (genetic variants, exposure and outcome) 
are linear and homogeneous for all individuals in the popula-
tion, then we would expect the variant-specific estimates (that 
is, the ratio estimates based on each variant in turn) to all target 
the same causal parameter, and for there to be no more hetero-
geneity between the variant-specific estimates than would be 
expected by chance alone12. However, there are many reasons 
why excess heterogeneity may occur in practice. These include 
statistical reasons (such as departure from linearity and homo-
geneity across individuals) and biological reasons. For instance, 
variants associated with body mass index (BMI) influence 
BMI via different biological mechanisms55. Additionally, some 
variants are associated with BMI from early childhood and others 
from adolescence or later. Variants that influence BMI for longer 
may be expected to have stronger proportional associations with 
chronic disease outcomes for which BMI is a cause. Hence if 
there is a true causal effect of the exposure on the outcome, 
some heterogeneity may be expected in the variant-specific 
causal estimates. However, heterogeneity would also arise if 
some genetic variants are not valid instrumental variables 
(see Section 6)56.
The IVW method can be performed using a fixed-effects or a 
random-effects meta-analysis model. Unless there are very few 
variants (meaning that heterogeneity between the variant-specific 
estimates cannot be estimated reliably) or all variants are taken 
from the same gene region, we recommend using a multiplicative 
random-effects model as the default option for the IVW 
method. If there is no more heterogeneity between the ratio esti-
mates for the individual variants than would be expected by chance 
alone, then the random-effect analysis is equivalent to the fixed-
effect analysis, and there is no loss of precision in making the 
weaker random-effects assumption. However, if there is excess 
heterogeneity, then the fixed-effect analysis is inappropriate, as 
its confidence intervals are misleadingly narrow. A multiplicative 
random-effects model is preferred to the additive 
random-effects model that is more common in the meta-analysis 
literature as it does not change the relative weighting of the variant- 
specific estimates32. In contrast, an additive random-effects model 
upweights outlying estimates, which are more likely to repre-
sent pleiotropic variants. The multiplicative random-effects IVW 
method provides valid causal estimates under the assumption of 
balanced pleiotropy; that is, pleiotropic effects on the outcome 
are equally likely to be positive as negative32.
We recommend the IVW method with multiplicative random-
effects as the primary analysis method for use with summarized 
data, because it is the most efficient analysis method with 
valid instrumental variables, and it accounts for heterogene-
ity in the variant-specific causal estimates. If a causal effect is 
detected using this method, then investigators should proceed to 
perform sensitivity analyses to assess the robustness of their 
finding to the assumption of balanced pleiotropy.
A scenario that requires a different approach to the primary analysis 
occurs when there are several related exposures that have shared 
genetic predictors, meaning that it is difficult to find specific 
predictors of the individual exposures. In this case, a multivariable 
Mendelian randomization approach may be the primary anal-
ysis strategy57. Multivariable Mendelian randomization is 
an extension to standard (univariable) Mendelian randomization 
that allows genetic variants to be associated with more than one 
exposure, and estimates the direct causal effects of each exposure 
in a single analysis model. The instrumental variable assump-
tions in multivariable Mendelian randomization require each 
variant to be associated with at least one of the exposures, not 
associated with the outcome via confounding, and not to affect 
the outcome except potentially via its association with one or 
more of the exposures included in the analysis model. For iden-
tification, it is also required that there is no perfect collinearity 
between the genetic associations; that is, there are variants that 
explain independent variation in each exposure58. Examples 
of exposure sets where multivariable Mendelian randomiza-
tion has been used include lipid fractions (such as high-density 
lipoprotein cholesterol, low-density lipoprotein (LDL) choles-
terol, and triglycerides)59, and body composition measures (such 
as fat mass and fat-free mass)60. Provided that genetic variants 
act as instrumental variables for the set of exposures, the direct 
causal effects of the individual exposures on the outcome can be 
estimated61. Both the 2SLS and IVW methods can be adapted 
to the multivariable setting58. A multivariable analysis 
strategy may also be worthwhile if genetic variants are associ-
ated with measured exposures that represent potentially pleio-
tropic pathways from the genetic variants to the outcome, as 
the effects of these exposures on the outcome will be accounted 
for in the multivariable analysis model (Section 7).
6. Robust methods for sensitivity analysis
A robust analysis method is defined here as a method that can 
provide valid causal inferences under weaker assumptions than 
the standard IVW method. Many robust analysis methods are 
available to detect and adjust for pleiotropy when using multiple 
genetic variants. Any polygenic Mendelian randomization inves-
tigation that does not perform one or more robust methods may 
be viewed as somewhat incomplete40,62; investigators should con-
sider using multiple methods that make different assumptions 
about the nature of the underlying pleiotropy27. Although 
robust methods typically use the term ‘pleiotropy’, there is a 
mathematical correspondence between instrument invalidity and 
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pleiotropy63, and so these methods can help assess sensitivity 
of findings to instrument invalidity more generally, and not 
simply invalidity that arises from horizontal pleiotropy. 
However, the robust methods are more likely to be effective for 
addressing instrument invalidity that arises due to issues such 
as pleiotropy or linkage disequilibrium with a variant influenc-
ing a confounder, which affect specific variants in a sporadic 
way, and less effective for instrument invalidity that arises due to 
issues such as population stratification or dynastic effects, which 
affect all variants in a systematic way. We here use the language 
of pleiotropy to make mathematically precise statements about 
the assumptions needed for methods to provide consistent 
estimates.
While a full comparison of all the robust methods that have 
been proposed is beyond the scope of this paper, a summary of 
several methods is provided as Table 1. This table is based on 
a broader review and comparison of methods27. We proceed 
to provide a brief description of some commonly used methods.
The most commonly used robust methods are MR-Egger, 
median- and mode-based methods, and MR-PRESSO. We 
focus on these methods here as they can be implemented using 
summarized data alone, and they rely on different assumptions 
to provide consistent causal estimates. The MR-Egger method 
estimates the causal effect as the slope from the weighted regres-
sion of the variant—outcome associations on the variant— 
exposure associations, and the average pleiotropic effect as 
the intercept. The method allows all genetic variants to have 
pleiotropic effects; however, it requires that the pleiotropic effects 
are independent of the variant–exposure associations (referred 
to as the Instrument Strength Independent of Direct Effect 
(InSIDE) assumption)19. A multivariable version of the MR-Egger 
method is available64. Estimates from the MR-Egger method are 
particularly affected by outlying and influential datapoints65, 
and are prone to be imprecise, particularly when the variant– 
exposure associations are all similar in magnitude. This can lead 
to the method having low power to detect a causal effect. A het-
erogeneity measure has been proposed to quantify the similarity 
between variant–exposure associations and the potential impact 
on MR-Egger analyses66. A Bayesian model averaging method 
has also been proposed, which averages over the IVW and 
MR-Egger results using weights based on the degree of pleiotropy 
observed in the data67.
The median- and mode-based methods20,21,68 rely on some genetic 
variants being valid instruments, but make weaker assumptions 
about the invalid instruments and are more robust to outliers. 
Specifically, the median-based method assumes that at least 
half of the variants are valid instruments (majority valid 
assumption), and the mode-based method assumes more variants 
estimate the true causal effect than estimate any other quantity 
(plurality valid assumption). Intuitively speaking, both meth-
ods take the variant-specific causal estimates (i.e. the ratio 
estimates based on the individual variants), and calculate a 
measure of central tendency of these estimates. These methods 
have a natural robustness to variants with outlying ratio 
estimates, and so are not as affected by the presence of a small 
number of pleiotropic variants as the IVW and MR-Egger 
methods. The mode-based method has been shown to have low 
precision in some simulated and real datasets27. Other methods 
have been proposed that make the same plurality valid assump-
tion as the mode-based method, including the contamination 
mixture method25 and MR-Mix26.
The MR-PRESSO method is a variation on the IVW method 
that first removes genetic variants from the analysis whose vari-
ant-specific causal estimate differs substantially from those 
of other variants22. The IVW method is then performed for all 
variants that are not judged to be heterogeneous.
While it would be excessive to perform every robust method for 
Mendelian randomization that has been proposed, or even all the 
methods mentioned here, investigators should pick a sensible 
range of methods to assess the sensitivity of their findings. A 
recommendation is to perform the MR-Egger, median-based 
method, and mode-based method, as these methods require 
different assumptions to be satisfied for asymptotically consistent 
estimates. If estimates from all methods are similar, then any 
causal claim is more credible. However, differences between 
estimates does not necessarily imply the absence of a causal 
effect. Different methods will perform better and worse in dif-
ferent scenarios, so critical thought and judgement is required. 
Two recent simulation studies that compared different methods 
recommended the contamination mixture method27 and MR-Mix69 
as having the lowest mean squared error across a range of 
different methods – these methods both make the same consistency 
assumption as the mode-based method, and so either could be 
used in preference to it.
We also recommend that a measure of the heterogeneity between 
variant-specific causal estimates, such as Cochran’s Q statistic 
or the I2 statistic, is reported as a part of a polygenic Mendelian 
randomization investigation56,70,71. Conclusions are more reliable 
when multiple genetic variants provide concordant evidence for 
a causal effect, and particularly when there is no more heteroge-
neity between the variant-specific causal estimates than expected 
by chance. As discussed in Section 5, some heterogeneity may 
be expected even when all genetic variants are valid instruments. 
However, causal conclusions are less reliable when there is 
substantial heterogeneity, especially when there are distinct out-
liers (which may represent pleiotropic variants) or when evidence 
for a causal effect depends on one or a small number of variants.
Leave-one-out analyses (i.e. remove one variant from the analysis 
and re-estimate the causal effect) can be valuable in assessing 
the reliance of a Mendelian randomization analysis on a par-
ticular variant72. If there is one genetic variant that is particularly 
strongly associated with the exposure, then it may dominate 
the estimate of the causal effect. Investigators should assess 
the robustness of findings to the removal of such variants. If a 
causal effect is only evidenced by one variant, then the valid-
ity of inference depends only on that variant. If there are many 
variants in an analysis, leaving one variant out at a time is unlikely 
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to change the estimate substantially, and leaving out subsets of 
the variants (say, a randomly chosen 30% at a time73) may be 
more appropriate. A further approach for identifying variants 
to remove from the analysis is Steiger filtering, which removes 
variants from the analysis if their association with the outcome 
is stronger than that with the exposure74. It is unlikely that vari-
ants could have a stronger association with the outcome than the 
exposure if the instrumental variable assumptions are satisfied 
and the genetic association with the outcome is entirely mediated 
via the exposure.
While removing horizontally pleiotropic variants from a 
Mendelian randomization analysis will improve the validity 
of causal inferences, there is some danger in a post hoc or 
data-driven selection of genetic variants. This is particularly 
true if many genetic variants are judged to be heterogene-
ous: the removal of too many variants from the analysis could 
provide a false impression of agreement amongst the remain-
ing variants, and over-precision in the causal estimate. Removing 
a variant from the analysis is more justified when a pleiotropic 
association of the variant has been identified75.
A further class of robust methods uses latent modelling to 
distinguish to what extent genetic associations with the 
outcome arise due to a causal effect of the exposure, as 
opposed to via direct (pleiotropic) or confounder-driven effects 
of particular variants. A causal model is evidenced if the 
predominance of variants that associate with the exposure 
also associate with the outcome in a proportional way. If the 
genetic associations with the outcome do not follow this pattern, 
then a non-causal explanation would be preferred. Emerging 
methods that take this approach include the Causal Analyses 
Using Summary Effect Estimates (CAUSE)76 and Latent 
Heritable Confounder Mendelian randomization (LHC-MR)77 
methods.
7. Other approaches for sensitivity analysis
Sensitivity analysis should not be limited to the application of 
different statistical methods. This is particularly important for 
investigations based on a single gene region, as several of the 
methods discussed above are not applicable in this case. Other 
approaches for assessing robustness include varying the data-
set and choice of genetic variants in the analysis (including the 
suggestion of liberal and conservative variant sets in Section 3), 
the use of positive and negative control outcomes and/or samples, 
colocalization, subgroup analyses, and examining associations 
with potentially pleiotropic variables. We continue to describe 
each of these in turn.
A positive control outcome is an outcome for which it is already 
established that the exposure is causal. For example, the out-
come of gout may be used as a positive control in a Mendelian 
randomization investigation for serum uric acid as an expo-
sure, as raised uric acid levels are known to increase risk of 
gout. Provided that there is sufficient statistical power, if genetic 
variants that are associated with serum uric acid are not also 
associated with risk of gout, then we may question whether the 
genetic variants are truly able to assess the effects of varying 
serum uric acid78. Conversely, a negative control outcome is 
an outcome for which it is believed that the exposure cannot be 
causal. For example, pre-pubertal asthma was used as a nega-
tive control outcome in a Mendelian randomization study on the 
effects of age at puberty on asthma79. If a Mendelian randomiza-
tion investigation suggests that the negative control is caused 
by the exposure, then violation of the instrumental variable 
assumptions (such as through pleiotropy) may be suspected.
Colocalization assesses whether the same genetic variant (or 
variants) influences two traits80,81. Even if genetic variants in 
a given gene region are associated with both an exposure and 
an outcome, this does not imply that the same genetic variants 
influence both exposure and outcome (implying the likely pres-
ence of a causal pathway including the exposure and outcome). 
It may be that the two associations are driven by different 
causal variants, and these variants are correlated due to linkage 
disequilibrium82. An example of this is the APOE gene region, in 
which genetic variants are associated with LDL-cholesterol and 
Alzheimer’s disease, but LDL-cholesterol does not appear to be 
a cause of Alzheimer’s disease83. Colocalization can be useful 
for assessing exposures such as proteins and gene expression, 
particularly when the Mendelian randomization analysis is based 
on a single gene region84. However, there are several limita-
tions to such an analysis, including whether gene expression 
is estimated in a relevant tissue. Although colocalization dif-
fers from Mendelian randomization in a number of ways, the 
approach can provide complementary evidence supporting or 
questioning the presence of a biological mechanism linking the 
exposure and outcome via a common genetic predictor.
A subgroup analysis compares Mendelian randomization esti-
mates (or equivalently genetic associations) estimated on 
different subgroups of the population in which the genetic vari-
ants have different degrees of association with the exposure. An 
example of subgroup analysis is the comparison of genetic asso-
ciations with blood pressure in men and women in an East Asian 
population for variants implicated in the metabolism of 
alcohol85,86. As women in East Asia tend not to drink alcohol, 
genetic associations with blood pressure are observed in men but 
not in women. Also, genetic associations are stronger in heavier 
drinkers85. This provides confidence that the genetic associa-
tions are driven by alcohol consumption and not by a pleiotropic 
mechanism. Such an analysis can be performed if there is a 
subgroup of the population that has reduced or increased levels of 
the exposure87,88. However, if the subgroup is defined by a collider 
(see below), then stratification can introduce bias to the analysis89. 
A further possible sensitivity analysis is to check the genetic 
associations with other variables associated with the outcome, 
and which are thought not to lie on the causal pathway through 
the exposure (i.e. are not mediators). Such variables may lie on 
alternative pleiotropic pathways to the outcome. If the genetic 
variants are not associated with such variables, then some 
reassurance can be drawn that the Mendelian randomization 
assumptions are satisfied. A further possibility in this case is to 
perform a multivariable Mendelian randomization, including the 
putative pleiotropic variables as additional exposures in the 
analysis model90. This analysis will estimate the direct effect of 
the exposure on the outcome keeping these variables constant. 
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Methods have been proposed based on a multivariable 
approach in the context of gene expression data, including the 
MR-link91, and transcriptome-wide summary statistics-based 
Mendelian Randomization (TWMR)92 methods.
There are several other potential sources of bias in a Mende-
lian randomization analysis other than invalid instruments. We 
consider here collider bias, selection bias, and reverse causation 
as three potential sources of bias, and direct readers to reviews 
that list further potential sources of bias45,93.
A collider is a common effect of two variables – for example, 
the any variable causally downstream of the exposure is 
influenced by the genetic variants and the exposure—outcome 
confounders, and so is a collider. Even if two variables are 
unrelated (they are marginally independent), they will typically 
be related when conditioning on the collider (conditionally 
dependent)89. Stratifying on or adjusting for a collider there-
fore leads to an association between variables that influ-
ence the collider. An association between the genetic variants 
and the exposure—outcome confounders would lead to 
biased causal estimates94. Collider bias is not unique to 
Mendelian randomization, but it is particularly relevant as some 
published genetic association estimates have been adjusted for 
potential colliders. Methods to account for collider bias have 
recently been proposed95.
Selection bias is a specific example of collider bias which 
occurs when selection into a study sample depends on a collider. 
Simulation studies have shown that selection bias can have a 
severe impact on Mendelian randomization estimates, but only 
when the associations of variables with the collider are quite 
strong49,94. Selection bias can potentially be addressed using 
inverse-probability weighting, although this requires estima-
tion of the probability of selection into the study sample for all 
individuals.
While the genetic code is fixed at conception and so cannot be 
influenced by reverse causation, if the outcome influences the 
risk factor, this can result in gene—outcome associations becom-
ing distorted and lead to misleading inferences. As discussed 
above and shown in Figure 4e, if genetic variants used as 
instrumental variables for the exposure in fact influence the 
outcome primarily, then genetic associations with the outcome 
could be present without the exposure influencing the outcome. 
The MR-Steiger method has been developed to detect such 
variants and remove them from the analysis74. Bidirectional 
Mendelian randomization analyses have been proposed that 
use separate sets of instrumental variables for the exposure and 
outcome to assess the direction of causal effect96.
8. Data presentation
An attractive feature of Mendelian randomization is that the 
analysis can be summarized graphically in a transparent way. For 
example, in a polygenic analysis, a scatter plot of the genetic asso-
ciations with the outcome against the genetic associations with 
the exposure reveals much about the analysis – whether different 
genetic variants provide similar estimates of the causal effect or 
if there is considerable heterogeneity, and whether the analysis 
is dominated by a single genetic variant or not29. The scatter 
plot is appealing as it presents the data with no manipula-
tion. Examples of scatter plots illustrating heterogeneity and 
no heterogeneity in the causal estimates from different variants 
are shown in Figure 5. Alternatives are forest plots, funnel plots, 
and radial plots – each of these assesses heterogeneity in the 
variant-specific causal estimates97. Plots allow the investigators 
and readers to assess the reliability of the analysis method and 
its underlying assumptions, and we strongly recommend their 
inclusion in a manuscript.
Other important information to report include the R2 statistic 
(when the exposure is continuous), which is a measure of the 
variance in the exposure explained by the genetic variants, and 
(particularly in a one-sample setting) the related F statistic, which 
is a measure of instrument strength and can be used to judge the 
extent of weak instrument bias98. Investigators can also make 
some statement about the power of their analysis. Power to detect 
a causal effect depends on the proportion of variance in the 
exposure explained by the genetic variants, proposed size of 
causal effect, sample size (for the genetic associations with 
the outcome), and (with a binary outcome) proportion of indi-
viduals with an outcome event. Power calculators can be found 
at http://cnsgenomics.com/shiny/mRnd/ and https://sb452.
shinyapps.io/power/. Power calculations are often performed 
post hoc, as sample sizes are rarely determined based on a 
proposed Mendelian randomization analysis. Power calculations 
are more meaningful when performed prior to the analysis, and 
can guide investigators which exposure/outcome pairs to con-
sider, and so focus on analyses that have a better chance of giving 
meaningful results.
9. Interpretation
Finally, we discuss the interpretation of findings from Mendelian 
randomization investigations. In the first instance, a Mendelian 
randomization investigation assesses the association of genetic 
predictors of an exposure with an outcome, or equivalently, 
the association of genetically-predicted levels of an expo-
sure with an outcome. Making causal inferences from obser-
vational data always relies on untestable assumptions. In 
Mendelian randomization, the assumption is that observed 
differences in the outcome associated with genetically pre-
dicted levels of the exposure would also be seen if the exposure 
were intervened on7,48. In line with the STROBE-MR guidelines1, 
we recommend that a cautious interpretation should be taken 
when describing the extent to which a causal effect has been 
demonstrated by a Mendelian randomization investigation. The 
appropriate degree of caution will depend on the plausibility of 
the instrumental variable assumptions, the concordance of esti-
mates from different methods and different analytical approaches, 
the results from sensitivity and supplementary analyses, and 
so on.
Mendelian randomization estimates relate specifically to 
changes in the exposure induced by the genetic variants used as 
instrumental variables. The genetic code is fixed at conception, 
and so Mendelian randomization investigations typically com-
pare groups of the population having different trajectories in 
their distribution of the exposure over time99. Analyses 
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Figure 5. Scatter plot of genetic associations with the outcome (vertical axis) against genetic associations with the exposure (horizontal 
axis). Examples illustrated are: (left) no heterogeneity in the variant-specific causal estimates (effect of LDL-cholesterol on coronary heart 
disease risk using 8 variants associated with LDL-cholesterol); and (right) heterogeneity in the variant-specific causal estimates (effect of 
C-reactive protein on coronary heart disease risk using 17 genome-wide significant predictors of C-reactive protein). As indicated by 
differences in estimates, not all genetic variants are valid instrumental variables for C-reactive protein, and so a causal interpretation is not 
appropriate. Taken from Burgess et al., 201868.
therefore typically can be interpreted as assessing the impact 
of long-term elevated levels of an exposure. However, in most 
cases, we have incomplete information about how the genetic 
variant changes the distribution of the exposure across the life 
course. If the genetic associations with the exposure vary over 
time, then Mendelian randomization estimates based on genetic 
associations with the exposure measured at a single timepoint 
can be unreliable31. Similar difficulties of interpretation arise 
if the impact on the outcome relates to levels of the exposure 
at a specific time period in life. A plausible example of this 
is the effect of vitamin D on multiple sclerosis; multiple sclero-
sis risk is hypothesized to be influenced by vitamin D levels 
during early childhood, but not vitamin D levels in adulthood100. 
If measurements of genetic associations with the exposure are 
available at different timepoints, then multivariable Mendelian 
randomization analyses can be performed to distinguish 
between the effect of the exposure at each time point101.
That said, results from Mendelian randomization investigations 
have often been shown to qualitatively agree with the results 
from randomized trials, suggesting that a causal interpreta-
tion for Mendelian randomization findings is often reasonable93. 
Mendelian randomization investigations are worthwhile in 
providing an alternative line of aetiological evidence even if 
though the instrumental variable assumptions can never be 
proved beyond all doubt102,103. However, quantitative differences 
between estimates from Mendelian randomization and from 
trials are likely, particularly as there are differences between how 
genetic variants influence the exposure and how clinical and 
pharmaceutical interventions influence the exposure104 As genetic 
variants typically affect usual levels of exposures on a long- 
term basis, Mendelian randomization estimates are often 
larger than those from conventional observational studies or 
randomized trials31. Hence, the causal estimate from a Mendelian 
randomization investigation should not generally be interpreted 
directly as the expected impact of intervening on the expo-
sure in applied practice105. The estimate from a Mendelian rand-
omization investigation is therefore better interpreted as a test 
statistic for a causal hypothesis rather than the estimated 
impact of a well-defined intervention at a specific point in 
time. But even when a Mendelian randomization investigation 
is performed primarily to assess the causal role of an exposure, 
causal estimates can still be useful, for example to assess 
heterogeneity in estimates from different variants as a test of 
instrument validity, or to compare results from different analysis 
methods as an assessment of robustness56. A logical consequence 
of the 2SLS/IVW method providing the most efficient causal 
estimate when combining evidence across multiple valid instru-
mental variables is that, under the same assumptions, the 
method provides the most powerful test of the presence of a 
causal effect.
Summary
Overall, the key elements of a Mendelian randomization inves-
tigation that we would expect to be present in any manu-
script are: i) motivation for why a Mendelian randomization 
analysis should be performed and for the scope of the analysis, 
ii) a clear description and justification of the choice of 
dataset(s) for the analysis, including why a one- or two-sample 
approach was chosen for the primary analysis, iii) a clear 
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description and justification of the choice of genetic variants 
used in the analysis, iv) a discussion, whether statistically or bio-
logically led, of whether the genetic variants are likely to satisfy 
the instrumental variable assumptions, v) a clear graphical pres-
entation of the data, such as a scatter plot of the genetic asso-
ciations, and vi) some attempt to test the robustness of the 
main findings, whether by use of robust methods (for a polygenic 
analysis) or another approach – whatever is most appropriate 
to the analysis under consideration. Without these elements, 
the reader is not fully able to judge the reliability of a 
Mendelian randomization investigation.
Particularly with the advent of summarized data and the 
two-sample setting, performing a Mendelian randomization 
analysis has become more straightforward28. The difficulty is not 
in performing a Mendelian randomization analysis, but rather 
in performing a credible analysis106 and providing a reasoned 
interpretation100. We hope that these guidelines, summarized 
in the accompanying flowcharts (Figure 1 and Figure 2) and 
checklist (Figure 3), will aid practitioners in performing reliable 
analyses, and editors and reviewers in judging the reliability of 
analyses, and that their use will help improve the overall quality 
of Mendelian randomization investigations.
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